IW 401

September 20, 2026 Viktor Zarev 0 min read
  1. Pharma companies aren’t completing postmarket drug studies. 
  2. ACGME suggests eliminating some work protections for residents. 
  3. Semaglutide is good for even frail heart disease patients. 
  4. Rise of GLP-1s is making life tough for food companies.
  5. Low patient volume drags down hospital operating margins. 
  6. Elective surgeries drop as patients lose healthcare coverage.
  7. CVS Aetna streamlines prior auths for cancer. 
  8. J&J sells closure device firm it bought just three years ago. 
  9. How will the Federal Reserve’s rate hike affect biotech stocks?
  10. Report: Agentic AI boom is outpacing governance efforts.
Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Structural Heart October 5, 2026

The Double Firsts of Edwards’ Autus Approval October 5, 2026

Children born with congenital pulmonary valve disease no longer need repeat surgeries throughout childhood with the FDA approval of Edwards Lifesciences' Autus Size-Adjustable Valve.

Cardiology Practices October 2, 2026

Can Rural Cardiology Be Revived? October 2, 2026

Nearly nine in ten rural counties lack a cardiologist and a new survey of the physicians serving the other 10% revealed that the issue runs deeper than […]

Cardiology Pharmaceuticals October 1, 2026

A New King of The GLP-1s Could Be Crowned October 1, 2026

Ladies and gents, Eli Lilly has outdone itself again, with the Phase 3 results of its triple GLP-1/GIP/glucagon receptor agonist, retatrutide, showing astonishing weight loss results for patients with obesity.